Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > eyes on the prize

<< Previous

Bullboard Posts

Next >>

Comment by YegJeeberon May 28, 2023 4:16pm

140 Views

Post# 35467998

RE:eyes on the prize

From what I've seen, and I admit it hasn't been great in depth research, is that biotechs are seemingly bought out prior to initiation of P3s, probably so the BP buyer can control and run the trial themselves. When Gilead bought Forty Seven for their product Macrolimab (??) for 4.9 billion, the trial was in Phase 1B if I am not mistaken.

Thoughts?

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024